Ontology highlight
ABSTRACT:
SUBMITTER: Becker PS
PROVIDER: S-EPMC4834701 | biostudies-literature | 2011 Oct
REPOSITORIES: biostudies-literature
Becker Pamela S PS Kantarjian Hagop M HM Appelbaum Frederick R FR Petersdorf Stephen H SH Storer Barry B Pierce Sherry S Shan Jianqin J Hendrie Paul C PC Pagel John M JM Shustov Andrei R AR Stirewalt Derek L DL Faderl Stephan S Harrington Elizabeth E Estey Elihu H EH
British journal of haematology 20110818 2
This phase I/II study was conducted to determine the maximum tolerated dose, toxicity, and efficacy of clofarabine in combination with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming (GCLAC), in the treatment of patients with relapsed or refractory acute myeloid leukaemia (AML). Dose escalation of clofarabine occurred without dose-limiting toxicity, so most patients were treated at the maximum dose, 25 mg/m(2) per day with cytarabine 2 g/m(2) per day, each for 5 d, ...[more]